Clinical trial
Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Naïve…
NCT00128232 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00128232 |
|---|---|
| Title | Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Naïve Acromegalic Patients |
| Official title | Safety and Efficacy of Octreotide LAR in Treatment Naïve Acromegalic Patients |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Acromegaly |
| Intervention type | Drug |
| Interventions | Octreotide LAR |
| Enrollment | 100 |
| Start date | Dec 1, 2002 |
| Primary completion | Aug 1, 2004 |
| First posted | Aug 9, 2005 |
| Last update posted | Apr 30, 2012 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: